Xochitl Luna Marti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xochitl Luna Marti has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Phillip Oliver Coffin
San Francisco Department of Public Health, Center on Substance Use and Health
4 shared publications - Vanessa M. McMahan
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
3 shared publications - Abby R. Dolan
Center for Emergency Care Policy and Research, University of Pennsylvania, Philadelphia
2 shared publications - Carolyn C. Cannuscio
University of Pennsylvania
2 shared publications - David A. Asch
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia
2 shared publications - David Grande
Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, USA
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (4) , e012683
Cardiovascular Conditions and Symptoms in Deaths Attributed to Acute Stimulant Toxicity
BACKGROUND: The underlying cause of deaths attributed to acute stimulant (methamphetamine or cocaine) toxicity is poorly understood, although cardiovascular events are believed to contribute. METHODS: We analyzed psychological autopsy data from acute stimulant toxicity deaths in San Francisco from 2022 to 2023. Sources included vital records, autopsies, medical records, and mixed-methods interviews with informants (eg, family and friends) who knew decedents in the year preceding death. We compared sociodemographic characteristics and cardiovascular measures (autopsy, ECG, echocardiogram, or laboratory abnormalities; diagnoses; acute care visits; symptoms) by fentanyl involvement. Age was skewed and compared with a Wilcoxon rank-sum test. Proportions were compared with χ 2 or Fisher exact tests. Qualitative thematic analyses identified themes related to cardiovascular health in interviews. RESULTS: Among 101 deaths, 70 involved stimulants without opioids and 31 also involved fentanyl. Median age at death was higher among stimulant without opioids compared with fentanyl-involved decedents (58 versus 50 years; P =0.02). A plurality were White (44%), and 36% were Black. Most (69%) were unhoused or marginally housed. Cardiovascular conditions were identified in records among 93% of stimulant without opioids and 71% of fentanyl-involved decedents ( P P =0.02). Specific conditions more prevalent among stimulant without opioid decedents were cardiac enlargement ( P =0.04), coronary artery disease ( P =0.01), prolonged QTc interval ( P =0.03), and hypertension ( P =0.02). Themes from 140 informant interviews included family history of cardiovascular disease, cardiovascular symptoms, comorbid conditions, reluctance to seek care, and poor health contributing to social isolation. CONCLUSIONS: Premortem cardiovascular conditions and symptoms were common among stimulant decedents and were more prevalent among deaths attributed to stimulants without opioids compared with those involving fentanyl. In addition to opioid overdose prevention efforts, people who use stimulants might benefit from aggressive prevention and treatment of cardiovascular disease.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (4) , e012683
Open AccessCardiovascular Conditions and Symptoms in Deaths Attributed to Acute Stimulant Toxicity
BACKGROUND: The underlying cause of deaths attributed to acute stimulant (methamphetamine or cocaine) toxicity is poorly understood, although cardiovascular events are believed to contribute. METHODS: We analyzed psychological autopsy data from acute stimulant toxicity deaths in San Francisco from 2022 to 2023. Sources included vital records, autopsies, medical records, and mixed-methods interviews with informants (eg, family and friends) who knew decedents in the year preceding death. We compared sociodemographic characteristics and cardiovascular measures (autopsy, ECG, echocardiogram, or laboratory abnormalities; diagnoses; acute care visits; symptoms) by fentanyl involvement. Age was skewed and compared with a Wilcoxon rank-sum test. Proportions were compared with χ 2 or Fisher exact tests. Qualitative thematic analyses identified themes related to cardiovascular health in interviews. RESULTS: Among 101 deaths, 70 involved stimulants without opioids and 31 also involved fentanyl. Median age at death was higher among stimulant without opioids compared with fentanyl-involved decedents (58 versus 50 years; P =0.02). A plurality were White (44%), and 36% were Black. Most (69%) were unhoused or marginally housed. Cardiovascular conditions were identified in records among 93% of stimulant without opioids and 71% of fentanyl-involved decedents ( P P =0.02). Specific conditions more prevalent among stimulant without opioid decedents were cardiac enlargement ( P =0.04), coronary artery disease ( P =0.01), prolonged QTc interval ( P =0.03), and hypertension ( P =0.02). Themes from 140 informant interviews included family history of cardiovascular disease, cardiovascular symptoms, comorbid conditions, reluctance to seek care, and poor health contributing to social isolation. CONCLUSIONS: Premortem cardiovascular conditions and symptoms were common among stimulant decedents and were more prevalent among deaths attributed to stimulants without opioids compared with those involving fentanyl. In addition to opioid overdose prevention efforts, people who use stimulants might benefit from aggressive prevention and treatment of cardiovascular disease.
- 12 November 2025
- Published by Elsevier in Addictive Behaviors
- Vol. 173, 108558
Witnessed overdose history and response among overdose survivors who use non-prescribed opioids in an overdose prevention trial
- 12 November 2025
- Published by Elsevier in Addictive Behaviors
- Vol. 173, 108558
Witnessed overdose history and response among overdose survivors who use non-prescribed opioids in an overdose prevention trial
- Open Access
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf280
Interest in Long-Acting Preexposure Prophylaxis (PrEP) Among Men at Risk for Human Immunodeficiency Virus Who Use Methamphetamine Participating in a Daily, Oral PrEP Adherence Trial in San Francisco, California
Background: Methamphetamine use is associated with increased risk for human immunodeficiency virus (HIV) and suboptimal adherence to daily, oral preexposure prophylaxis (PrEP). Long-acting PrEP is a promising HIV prevention method for people who use methamphetamine. Methods: We conducted interviews with participants of a daily, oral PrEP adherence trial at their final visit. Participants were assigned male at birth and reported past-month methamphetamine use and past-year condomless sex with a partner with HIV or unknown status. We conducted a thematic analysis of interview transcripts to assess experiences with daily, oral PrEP and interest in long-acting PrEP. Results: Of 23 participants, median age was 42 (interquartile range, 33–48) years, all were cisgender men, most were White (73%), and approximately half had been homeless or lived in a shelter in the past year (52%). The most common daily, oral PrEP adherence challenges were forgetting to take the medication, followed by not having the medication available and competing priorities. Most participants (91%) were interested in long-acting PrEP. A plurality (43%) preferred injection as the modality, 39% preferred a long-acting pill, and 17% an implant. Most concerns about long-acting PrEP regarded the implant, including the length of time drug is in the body and the insertion/removal procedure; frequent clinic visits were another concern. Conclusions: Most participants who used methamphetamine were interested in and described barriers to daily medications that could be mitigated by long-acting PrEP. Injections were the most preferred modality, although long-acting oral PrEP alleviated concerns for some. Future research should assess optimization of long-acting PrEP delivery to this at-risk population. Clinical Trials Registration. NCT04523519.
- 28 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf280
Open AccessInterest in Long-Acting Preexposure Prophylaxis (PrEP) Among Men at Risk for Human Immunodeficiency Virus Who Use Methamphetamine Participating in a Daily, Oral PrEP Adherence Trial in San Francisco, California
Background: Methamphetamine use is associated with increased risk for human immunodeficiency virus (HIV) and suboptimal adherence to daily, oral preexposure prophylaxis (PrEP). Long-acting PrEP is a promising HIV prevention method for people who use methamphetamine. Methods: We conducted interviews with participants of a daily, oral PrEP adherence trial at their final visit. Participants were assigned male at birth and reported past-month methamphetamine use and past-year condomless sex with a partner with HIV or unknown status. We conducted a thematic analysis of interview transcripts to assess experiences with daily, oral PrEP and interest in long-acting PrEP. Results: Of 23 participants, median age was 42 (interquartile range, 33–48) years, all were cisgender men, most were White (73%), and approximately half had been homeless or lived in a shelter in the past year (52%). The most common daily, oral PrEP adherence challenges were forgetting to take the medication, followed by not having the medication available and competing priorities. Most participants (91%) were interested in long-acting PrEP. A plurality (43%) preferred injection as the modality, 39% preferred a long-acting pill, and 17% an implant. Most concerns about long-acting PrEP regarded the implant, including the length of time drug is in the body and the insertion/removal procedure; frequent clinic visits were another concern. Conclusions: Most participants who used methamphetamine were interested in and described barriers to daily medications that could be mitigated by long-acting PrEP. Injections were the most preferred modality, although long-acting oral PrEP alleviated concerns for some. Future research should assess optimization of long-acting PrEP delivery to this at-risk population. Clinical Trials Registration. NCT04523519.
- Open Access
- 13 January 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e64873
Identification of Behavioral, Clinical, and Psychological Antecedents of Acute Stimulant Poisoning: Development and Implementation of a Mixed Methods Psychological Autopsy Study
Background: Despite increasing fatal stimulant poisoning in the United States, little is understood about the mechanism of death. The psychological autopsy (PA) has long been used to distinguish the manner of death in equivocal cases, including opioid overdose, but has not been used to explicitly explore stimulant mortality. Objective: We aimed to develop and implement a large PA study to identify antecedents of fatal stimulant poisoning, seeking to maximize data gathering and ethical interactions during the collateral interviews. Methods: We ascertained death records from the California Electronic Death Reporting System (CA-EDRS) and the San Francisco Office of the County Medical Examiner (OCME) from June 2022 through December 2023. We selected deaths determined to be due to acute poisoning from cocaine or methamphetamine, which occurred 3‐12 months prior and were not attributed to suicide or homicide. We identified 31 stimulant-fentanyl and 70 stimulant-no-opioid decedents. We sought 2 informants for each decedent, who were able to describe the decedent across their life course. Informants were at least 18 years of age, communicated with the decedent within the year before death, and were aware that the decedent had been using substances during that year. Upon completion of at least one informant interview conducted by staff with bachelor’s or master’s degrees, we collected OCME, medical record, and substance use disorder treatment data for the decedent. Planned analyses include least absolute shrinkage and selection operator regressions of quantitative data and thematic analyses of qualitative data. Results: We identified and interviewed at least one informant (N=141) for each decedent (N=101). Based on feedback during recruitment, we adapted language to improve rapport, including changing the term “accidental death” to “premature death,” offering condolences, and providing content warnings. As expected, family members were able to provide more data about the decedent’s childhood and adolescence, and nonfamily informants provided more data regarding events proximal to death. We found that the interviews were stressful for both the interviewee and interviewer, especially when participants thought the study was intrusive or experienced significant grief during the interviews. Conclusions: In developing and implementing PA research on fatal stimulant poisoning, we noted the importance of recruitment language regarding cause of death and condolences with collateral informants. Compassion and respect were critical to facilitate the interview process and maintain an ethical framework. We discuss several barriers to success and lessons learned while conducting PA interviews, as well as recommendations for future PA studies.
- 13 January 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e64873
Open AccessIdentification of Behavioral, Clinical, and Psychological Antecedents of Acute Stimulant Poisoning: Development and Implementation of a Mixed Methods Psychological Autopsy Study
Background: Despite increasing fatal stimulant poisoning in the United States, little is understood about the mechanism of death. The psychological autopsy (PA) has long been used to distinguish the manner of death in equivocal cases, including opioid overdose, but has not been used to explicitly explore stimulant mortality. Objective: We aimed to develop and implement a large PA study to identify antecedents of fatal stimulant poisoning, seeking to maximize data gathering and ethical interactions during the collateral interviews. Methods: We ascertained death records from the California Electronic Death Reporting System (CA-EDRS) and the San Francisco Office of the County Medical Examiner (OCME) from June 2022 through December 2023. We selected deaths determined to be due to acute poisoning from cocaine or methamphetamine, which occurred 3‐12 months prior and were not attributed to suicide or homicide. We identified 31 stimulant-fentanyl and 70 stimulant-no-opioid decedents. We sought 2 informants for each decedent, who were able to describe the decedent across their life course. Informants were at least 18 years of age, communicated with the decedent within the year before death, and were aware that the decedent had been using substances during that year. Upon completion of at least one informant interview conducted by staff with bachelor’s or master’s degrees, we collected OCME, medical record, and substance use disorder treatment data for the decedent. Planned analyses include least absolute shrinkage and selection operator regressions of quantitative data and thematic analyses of qualitative data. Results: We identified and interviewed at least one informant (N=141) for each decedent (N=101). Based on feedback during recruitment, we adapted language to improve rapport, including changing the term “accidental death” to “premature death,” offering condolences, and providing content warnings. As expected, family members were able to provide more data about the decedent’s childhood and adolescence, and nonfamily informants provided more data regarding events proximal to death. We found that the interviews were stressful for both the interviewee and interviewer, especially when participants thought the study was intrusive or experienced significant grief during the interviews. Conclusions: In developing and implementing PA research on fatal stimulant poisoning, we noted the importance of recruitment language regarding cause of death and condolences with collateral informants. Compassion and respect were critical to facilitate the interview process and maintain an ethical framework. We discuss several barriers to success and lessons learned while conducting PA interviews, as well as recommendations for future PA studies.
- Open Access
- 9 June 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (6) , e29395
Consumer Views on Health Applications of Consumer Digital Data and Health Privacy Among US Adults: Qualitative Interview Study
Background: In 2020, the number of internet users surpassed 4.6 billion. Individuals who create and share digital data can leave a trail of information about their habits and preferences that collectively generate a digital footprint. Studies have shown that digital footprints can reveal important information regarding an individual’s health status, ranging from diet and exercise to depression. Uses of digital applications have accelerated during the COVID-19 pandemic where public health organizations have utilized technology to reduce the burden of transmission, ultimately leading to policy discussions about digital health privacy. Though US consumers report feeling concerned about the way their personal data is used, they continue to use digital technologies. Objective: This study aimed to understand the extent to which consumers recognize possible health applications of their digital data and identify their most salient concerns around digital health privacy. Methods: We conducted semistructured interviews with a diverse national sample of US adults from November 2018 to January 2019. Participants were recruited from the Ipsos KnowledgePanel, a nationally representative panel. Participants were asked to reflect on their own use of digital technology, rate various sources of digital information, and consider several hypothetical scenarios with varying sources and health-related applications of personal digital information. Results: The final cohort included a diverse national sample of 45 US consumers. Participants were generally unaware what consumer digital data might reveal about their health. They also revealed limited knowledge of current data collection and aggregation practices. When responding to specific scenarios with health-related applications of data, they had difficulty weighing the benefits and harms but expressed a desire for privacy protection. They saw benefits in using digital data to improve health, but wanted limits to health programs’ use of consumer digital data. Conclusions: Current privacy restrictions on health-related data are premised on the notion that these data are derived only from medical encounters. Given that an increasing amount of health-related data is derived from digital footprints in consumer settings, our findings suggest the need for greater transparency of data collection and uses, and broader health privacy protections.
- 9 June 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (6) , e29395
Open AccessConsumer Views on Health Applications of Consumer Digital Data and Health Privacy Among US Adults: Qualitative Interview Study
Background: In 2020, the number of internet users surpassed 4.6 billion. Individuals who create and share digital data can leave a trail of information about their habits and preferences that collectively generate a digital footprint. Studies have shown that digital footprints can reveal important information regarding an individual’s health status, ranging from diet and exercise to depression. Uses of digital applications have accelerated during the COVID-19 pandemic where public health organizations have utilized technology to reduce the burden of transmission, ultimately leading to policy discussions about digital health privacy. Though US consumers report feeling concerned about the way their personal data is used, they continue to use digital technologies. Objective: This study aimed to understand the extent to which consumers recognize possible health applications of their digital data and identify their most salient concerns around digital health privacy. Methods: We conducted semistructured interviews with a diverse national sample of US adults from November 2018 to January 2019. Participants were recruited from the Ipsos KnowledgePanel, a nationally representative panel. Participants were asked to reflect on their own use of digital technology, rate various sources of digital information, and consider several hypothetical scenarios with varying sources and health-related applications of personal digital information. Results: The final cohort included a diverse national sample of 45 US consumers. Participants were generally unaware what consumer digital data might reveal about their health. They also revealed limited knowledge of current data collection and aggregation practices. When responding to specific scenarios with health-related applications of data, they had difficulty weighing the benefits and harms but expressed a desire for privacy protection. They saw benefits in using digital data to improve health, but wanted limits to health programs’ use of consumer digital data. Conclusions: Current privacy restrictions on health-related data are premised on the notion that these data are derived only from medical encounters. Given that an increasing amount of health-related data is derived from digital footprints in consumer settings, our findings suggest the need for greater transparency of data collection and uses, and broader health privacy protections.
- Open Access
- 5 April 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Consumer Views on Health Applications of Consumer Digital Data and Health Privacy Among US Adults: Qualitative Interview Study (Preprint)
BACKGROUND In 2020, the number of internet users surpassed 4.6 billion. Individuals who create and share digital data can leave a trail of information about their habits and preferences that collectively generate a digital footprint. Studies have shown that digital footprints can reveal important information regarding an individual’s health status, ranging from diet and exercise to depression. Uses of digital applications have accelerated during the COVID-19 pandemic where public health organizations have utilized technology to reduce the burden of transmission, ultimately leading to policy discussions about digital health privacy. Though US consumers report feeling concerned about the way their personal data is used, they continue to use digital technologies. OBJECTIVE This study aimed to understand the extent to which consumers recognize possible health applications of their digital data and identify their most salient concerns around digital health privacy. METHODS We conducted semistructured interviews with a diverse national sample of US adults from November 2018 to January 2019. Participants were recruited from the Ipsos KnowledgePanel, a nationally representative panel. Participants were asked to reflect on their own use of digital technology, rate various sources of digital information, and consider several hypothetical scenarios with varying sources and health-related applications of personal digital information. RESULTS The final cohort included a diverse national sample of 45 US consumers. Participants were generally unaware what consumer digital data might reveal about their health. They also revealed limited knowledge of current data collection and aggregation practices. When responding to specific scenarios with health-related applications of data, they had difficulty weighing the benefits and harms but expressed a desire for privacy protection. They saw benefits in using digital data to improve health, but wanted limits to health programs’ use of consumer digital data. CONCLUSIONS Current privacy restrictions on health-related data are premised on the notion that these data are derived only from medical encounters. Given that an increasing amount of health-related data is derived from digital footprints in consumer settings, our findings suggest the need for greater transparency of data collection and uses, and broader health privacy protections.
- 5 April 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessConsumer Views on Health Applications of Consumer Digital Data and Health Privacy Among US Adults: Qualitative Interview Study (Preprint)
BACKGROUND In 2020, the number of internet users surpassed 4.6 billion. Individuals who create and share digital data can leave a trail of information about their habits and preferences that collectively generate a digital footprint. Studies have shown that digital footprints can reveal important information regarding an individual’s health status, ranging from diet and exercise to depression. Uses of digital applications have accelerated during the COVID-19 pandemic where public health organizations have utilized technology to reduce the burden of transmission, ultimately leading to policy discussions about digital health privacy. Though US consumers report feeling concerned about the way their personal data is used, they continue to use digital technologies. OBJECTIVE This study aimed to understand the extent to which consumers recognize possible health applications of their digital data and identify their most salient concerns around digital health privacy. METHODS We conducted semistructured interviews with a diverse national sample of US adults from November 2018 to January 2019. Participants were recruited from the Ipsos KnowledgePanel, a nationally representative panel. Participants were asked to reflect on their own use of digital technology, rate various sources of digital information, and consider several hypothetical scenarios with varying sources and health-related applications of personal digital information. RESULTS The final cohort included a diverse national sample of 45 US consumers. Participants were generally unaware what consumer digital data might reveal about their health. They also revealed limited knowledge of current data collection and aggregation practices. When responding to specific scenarios with health-related applications of data, they had difficulty weighing the benefits and harms but expressed a desire for privacy protection. They saw benefits in using digital data to improve health, but wanted limits to health programs’ use of consumer digital data. CONCLUSIONS Current privacy restrictions on health-related data are premised on the notion that these data are derived only from medical encounters. Given that an increasing amount of health-related data is derived from digital footprints in consumer settings, our findings suggest the need for greater transparency of data collection and uses, and broader health privacy protections.